The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
Open accessAbstract
BACKGROUND: Long-term trends in excess risk of death and cardiovascular outcomes have not been extensively studied in persons with type 1 diabetes or type 2 diabetes. METHODS: We included patients registered in the Swedish National Diabetes Register from 1998 through 2012 and followed them through 2014. Trends in deaths and cardiovascular events were estimated with Cox regression and standardized incidence rates. For each patient, controls who were matched for age, sex, and county were randomly selected from the general population. RESULTS: Among patients with type 1 diabetes, absolute changes during the study period in the incidence rates of sentinel outcomes per 10,000 person-years were as follows: death from any cause, -31.4 (95% confidence interval [CI], -56.1 to -6.7); death from cardiovascular disease, -26.0 (95% CI, -42.6 to -9.4); death from coronary heart disease, -21.7 (95% CI, -37.1 to -6.4); and hospitalization for cardiovascular disease, -45.7 (95% CI, -71.4 to -20.1). Absolute changes per 10,000 person-years among patients with type 2 diabetes were as follows: death from any cause, -69.6 (95% CI, -95.9 to -43.2); death from cardiovascular disease, -110.0 (95% CI, -128.9 to -91.1); death from coronary heart disease, -91.9 (95% CI, -108.9 to -75.0); and hospitalization for cardiovascular disease, -203.6 (95% CI, -230.9 to -176.3). Patients with type 1 diabetes had roughly 40% greater reduction in cardiovascular outcomes than controls, and patients with type 2 diabetes had roughly 20% greater reduction than controls. Reductions in fatal outcomes were similar in patients with type 1 diabetes and controls, whereas patients with type 2 diabetes had smaller reductions in fatal outcomes than controls. CONCLUSIONS: In Sweden from 1998 through 2014, mortality and the incidence of cardiovascular outcomes declined substantially among persons with diabetes, although fatal outcomes declined less among those with type 2 diabetes than among controls. (Funded by the Swedish Association of Local Authorities and Regions and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Atherosclerotic cardiovascular disease (ASCVD) broadly refers to a history of acute coronary syndrome, myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral artery disease (PAD) including aortic aneurysm and is the leading cause of morbidity and mortality in people with diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ASCVD broadly refers to a history of acute coronary syndrome, myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, or peripheral artery disease (PAD) including aortic aneurysm and is the leading cause of morbidity and mortality in people with diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Under the current paradigm of comprehensive risk factor modification, cardiovascular morbidity and mortality have notably decreased in people with both type 1 and type 2 diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Under the current paradigm of comprehensive risk factor modification, cardiovascular morbidity and mortality have notably decreased in people with both type 1 and type 2 diabetes (1).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [1]
In the citing paper
“T2DM is common among patients with ASCVD or at the highest risk of CVD.The converse is also true: ASCVD is common in patients with T2DM.148”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [148]
In the citing paper
“Diabetes is a well-established risk factor for ischaemic heart disease (IHD), and CAD accounts for 40-80% of deaths in patients with T2DM.148,359,381”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [148]
In the citing paper
“These results were consistent across subgroups including those with and without diabetes or CKD.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“The primary outcome of worsening HF or CVD death was significantly reduced, 16.3% versus 21.2% for dapagliflozin compared with placebo (HR, 0.74; 95% CI, 0.65–0.85).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“Patients with T2DM are at high risk for ASCVD and HF compared with nondiabetic individuals (50,53).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
In the citing paper
“DAPA-HF was the first clinical trial of an SGLT2 inhibitor to assess HF events as the primary outcome and to include participants with and without diabetes (50).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
Whiting, D. R., Guariguata, L., Weil, C., & Shaw, J. E. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.029 · Cited by 4,018
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,000
RBPs Play Important Roles in Vascular Endothelial Dysfunction Under Diabetic Conditions
Yang, C., Kelaini, S., Caines, R., & Margariti, A. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01310 · Cited by 28
Grip, E. T., Svensson, A., Miftaraj, M., Eliasson, B., Franzén, S., Guðbjörnsdóttir, S., & Carlsson, K. S. (2019) · Diabetes Care · doi:10.2337/dc18-1850 · Cited by 28
Self-citationHosseini, M. M., Zargoush, M., Alemi, F., & Kheirbek, R. (2020) · Journal Of Big Data · doi:10.1186/s40537-020-00302-z · Cited by 27
The Putative Role of Methylglyoxal in Arterial Stiffening: A Review
van der Bruggen, M. M., Spronck, B., Delhaas, T., Reesink, K. D., & Schalkwijk, C. G. (2021) · Heart Lung and Circulation · doi:10.1016/j.hlc.2021.06.527 · Cited by 27
Schweiger, D. Š., Battelino, T., & Grošelj, U. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910192 · Cited by 27
Hallström, S., Wijkman, M. O., Ludvigsson, J., Ekman, P., Pfeffer, M. A., Wedel, H., Rosengren, A., & Lind, M. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100469 · Cited by 30
Self-citationYuan, J., Liu, Y., Zhou, L., Xue, Y., Lu, Z., & Gan, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.686293 · Cited by 27
Risk of Ischemic and Hemorrhagic Stroke in Individuals With Type 1 and Type 2 Diabetes
Mavridis, A., Viktorisson, A., Eliasson, B., von Euler, M., & Sunnerhagen, K. S. (2025) · Neurology · doi:10.1212/wnl.0000000000213480 · Cited by 26
Self-citationTreating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus
Trang, A., & Aguilar, D. A. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0371-7 · Cited by 26
Hanssen, N. M. J., Scheijen, J. L. J. M., Houben, A. J. H. M., van de Waarenburg, M. P. H., Berendschot, T. T. J. M., Webers, C. A. B., Reesink, K. D., van Greevenbroek, M. M. J., Kallen, C., Schaper, N. C., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.02.002 · Cited by 26
Gómez‐Huelgas, R., Sanz‐Cánovas, J., Cobos-Palacios, L., Sampalo, A. L., & Perez-Belmonte, L. M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.11.008 · Cited by 26
Ferreira-Divino, L. F., Suvitaival, T., Curovic, V. R., Tofte, N., Trôst, K., Mattila, I. M., Theilade, S., Winther, S. A., Hansen, T. W., Frimodt‐Møller, M., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01568-8 · Cited by 26
Saigusa, R., Vallejo, J., Gulati, R., Suthahar, S. S. A., Suryawanshi, V., Alimadadi, A., Makings, J., Durant, C. P., Freuchet, A., Roy, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179875 · Cited by 26
Exercise and nutrition in type 1 diabetes: Insights from the FinnDiane cohort
Barlovič, D. P., Harjutsalo, V., & Groop, P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1064185 · Cited by 26
Effect of low dose Semaglutide in people with Type 1 Diabetes and excess weight
Grassi, B. A., Onetto, M. T., Sánchez, C., Tapia, N., & Salas, F. M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111593 · Cited by 26
Jin, Q., Lau, E. S. H., Luk, A. O. Y., Tam, C. H. T., Ozaki, R., Lim, C. K. P., Wu, H., Chow, E., Kong, A. P. S., Lee, H. M., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06108-5 · Cited by 29
Kim, D., Li, A. A., Cholankeril, G. T., Kim, S. H., Ingelsson, E., Knowles, J. W., Harrington, R. A., & Ahmed, A. (2019) · Diabetologia · doi:10.1007/s00125-019-4870-9 · Cited by 27
Effects of sodium glucose cotransporter type 2 inhibitors on heart failure
Nassif, M. E., & Kosiborod, M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13678 · Cited by 26
Yang, T., Zhang, L., Yi, L., Feng, H., Li, S., Chen, H., Zhu, J., Zhao, J. H., Zeng, Y., & Liu, H. (2020) · JMIR Medical Informatics · doi:10.2196/15431 · Cited by 26
Scarale, M. G., Copetti, M., Garofolo, M., Fontana, A., Salvemini, L., Cosmo, S. D., Lamacchia, O., Penno, G., Trischitta, V., & Menzaghi, C. (2020) · Diabetes Care · doi:10.2337/dc19-2489 · Cited by 26
Adjuvant immunotherapy: the sting in the tail
Higham, C., Chatzimavridou-Grigoriadou, V., Fitzgerald, C. T., Trainer, P. J., Eggermont, A. M. M., & Lorigan, P. C. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.016 · Cited by 25
KIM, G. K., DeSalvo, D. J., Guffey, D., Minard, C. G., Cephus, C. E., Moodie, D. S., & Lyons, S. K. (2020) · International Journal of Pediatric Endocrinology · doi:10.1186/s13633-020-00081-7 · Cited by 25
Kerschbaum, J., Rudnicki, M., Dzien, A., Dzien‐Bischinger, C., Winner, H., Heerspink, H. J. L., Rosivall, L., Więcek, A., Mark, P. B., Eder, S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76773-0 · Cited by 25
Long Non-Coding RNAs (lncRNAs) in Cardiovascular Disease Complication of Type 2 Diabetes
Ismail, N., Abdullah, N., Murad, N. A. A., Jamal, R., & Sulaiman, S. A. (2021) · Diagnostics · doi:10.3390/diagnostics11010145 · Cited by 26
Managing dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 25
López‐de‐Andrés, A., Jiménez‐García, R., Hernández‐Barrera, V., de Miguel-Yanes, J. M., Albaladejo‐Vicente, R., Villanueva-Orbáiz, R., Carabantes-Alarcón, D., Zamorano‐León, J. J., López‐Herránz, M., & de Miguel‐Díez, J. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01273-y · Cited by 25
Myhre, P. L., Lyngbakken, M. N., Berge, T., Røysland, R., Aagaard, E. N., Pervez, O., Kvisvik, B., Brynildsen, J., Norseth, J., Tveit, A., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020447 · Cited by 25
Diabetes Increases Severe COVID-19 Outcomes Primarily in Younger Adults
Diedisheim, M., Dancoisne, E., Gautier, J., Larger, É., Cosson, E., Fève, B., Chanson, P., Czernichow, S., Tatulashvili, S., Raffin‐Sanson, M., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab393 · Cited by 25
Research Progress on Epigenetics of Diabetic Cardiomyopathy in Type 2 Diabetes
Deng, J., Liao, Y., Liu, J., Liu, W., & Yan, D. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.777258 · Cited by 25
Gyldenkerne, C., Mæng, M., Kjøller‐Hansen, L., Maehara, A., Zhou, Z., Ben‐Yehuda, O., Bøtker, H. E., Engstrøm, T., Matsumura, M., Mintz, G. S., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.061983 · Cited by 25
Jin, Q., Lau, E. S. H., Luk, A. O. Y., Tam, C. H. T., Ozaki, R., Lim, C. K. P., Wu, H., Chow, E., Kong, A. P. S., Lee, H. M., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01726-y · Cited by 25
Karakasis, P., Patoulias, D., Pamporis, K., Popovic, D. S., Stachteas, P., Bougioukas, K. I., Fragakis, N., & Rizzo, M. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15259 · Cited by 25
Monocyte and macrophage foam cells in diabetes-accelerated atherosclerosis
Cervantes, J., & Kanter, J. E. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1213177 · Cited by 24
Patsoukaki, V., Lind, L., Lampa, E., Radhi, S. H., Eeg‐Olofsson, K., Eliasson, B., & Eriksson, J. W. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00165-2 · Cited by 24
Self-citationAndersson, T., Hjerpe, P., Carlsson, A. C., Pivodic, A., Wändell, P. E., Manhem, K., & Boström, K. B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.01.038 · Cited by 24
Disparities in mortality among adults with and without diabetes by sex and race
Mansour, O., Golden, S. H., & Yeh, H. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107496 · Cited by 25
Montagud‐Marrahí, E., Molina-Andújar, A., Pané, A., Ruiz, S., Amor, A. J., Esmatjes, E., Ferrer, J., Banon-Maneus, E., Hermida, E., Musquera, M., et al. (2021) · Transplantation · doi:10.1097/tp.0000000000003710 · Cited by 26
Risk of cardiovascular events associated with pathophysiological phenotypes of type 2 diabetes
Stidsen, J. V., Christensen, D. H., Henriksen, J. E., Højlund, K., Olsen, M. H., Thomsen, R. W., Christensen, L. B., Nielsen, J. S., Olesen, T. B., & Beck‐Nielsen, H. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0020 · Cited by 24
Bebu, I., Braffett, B. H., de Boer, I. H., Aiello, L. P., Bantle, J. P., Lorenzi, G. M., Herman, W. H., Gubitosi‐Klug, R., Perkins, B. A., Lachin, J. M., et al. (2022) · Diabetes Care · doi:10.2337/dc22-1744 · Cited by 24
Ortiz, F., Harjutsalo, V., Helanterä, I., Lempinen, M., Forsblom, C. M., & Groop, P. (2018) · Diabetes Care · doi:10.2337/dc18-1029 · Cited by 24
Perco, P., Pena, M. J., Heerspink, H. J. L., & Mayer, G. J. (2018) · Kidney International Reports · doi:10.1016/j.ekir.2018.12.001 · Cited by 25
Succurro, E., Fiorentino, T. V., Miceli, S., Perticone, M., Sciacqua, A., Andreozzi, F., & Sesti, G. (2020) · Diabetes Care · doi:10.2337/dc20-1401 · Cited by 24
Rautio, E., Gadler, F., Gudbjörnsdottir, S., Franzén, S., Rydén, L., Svensson, A.-M., & Mellbin, L. G. (2020) · Diabetes Care · doi:10.2337/dc20-0084 · Cited by 23
Self-citationPharmacological management of type 2 diabetes: what’s new in 2017?
Scheen, A. J. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1376652 · Cited by 23
Zoni, S., Verga, M.-E., Hauschild, M., Aquarone, M.-P., Gyuriga, T., Ramelet, A., & Dwyer, A. A. (2017) · Journal of Pediatric Nursing · doi:10.1016/j.pedn.2017.11.015 · Cited by 23
Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?
Connelly, K. A., Bhatt, D. L., & Verma, S. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.11.010 · Cited by 23
Diabetes and Vascular Disease: Is It All About Glycemia?
Vecchié, A., Montecucco, F., Carbone, F., Dallegri, F., & Bonaventura, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190830181944 · Cited by 23
Antikainen, A. A., Sandholm, N., Trégouët, D., Charmet, R., McKnight, A. J., Ahluwalia, T. S., Syreeni, A., Valo, E., Forsblom, C. M., Gordin, D., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa045 · Cited by 23
Chun, H. S., Lee, J. S., Lee, H. W., Kim, B. K., Park, J. Y., Kim, D. Y., Ahn, S. H., Lee, Y., Kim, Y. D., & Kim, S. U. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15387 · Cited by 23
Tommerdahl, K. L., Baumgartner, K. V., Schäfer, M., Bjornstad, P., Melena, I. L., Hegemann, S., Baumgartner, A., Pyle, L., Cree‐Green, M., Truong, U. T., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1879 · Cited by 23
PHD Finger Protein 19 Promotes Cardiac Hypertrophy via Epigenetically Regulating SIRT2
Gu, W., Cheng, Y., Wang, S., Sun, T., & Li, Z. (2021) · Cardiovascular Toxicology · doi:10.1007/s12012-021-09639-0 · Cited by 23
Atale, N., Mishra, C. B., Kohli, S., Mongre, R. K., Prakash, A., Kumari, S., Yadav, U. C. S., Jeon, R., & Rani, V. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/8839479 · Cited by 23
Lee, S. H., & Park, J. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0036 · Cited by 23
Development and Future of Automated Insulin Delivery (AID) Systems
Garg, S. K., & MCVEAN, J. J. F. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0467 · Cited by 25
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
Caturano, A., Galiero, R., Rocco, M. P., Tagliaferri, G., Piacevole, A., Nilo, D., Lorenzo, G. D., Sardu, C., Vetrano, E., Monda, M., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092039 · Cited by 25
Cheng, P. C., Hsu, S. R., Cheng, Y. C., & Liu, Y. H. (2017) · PeerJ · doi:10.7717/peerj.3875 · Cited by 23
Heart failure mortality compared between elderly and non-elderly Thai patients.
Krittayaphong, R., Karaketklang, K., Yindeengam, A., & Janwanishstaporn, S. (2018) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2018.12.006 · Cited by 23
Yiannoullou, P., Summers, A., Goh, S. C., Fullwood, C., Khambalia, H. A., Moinuddin, Z. M., Shapey, I. M., Naish, J. H., Miller, C., Augustine, T., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2111 · Cited by 23
Seghieri, G., Policardo, L., Gualdani, E., Anichini, R., & Francesconi, P. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01292-y · Cited by 23
Darsalia, V., Johansen, O. E., Lietzau, G., Nyström, T., Klein, T., & Patrone, C. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00493 · Cited by 23
Krittayaphong, R., Muenkaew, M., Chiewvit, P., Ratanasit, N. C., Kaolawanich, Y., & Phrommintikul, A. (2019) · PubMed Central · doi:10.11909/j.issn.1671-5411.2019.08.004 · Cited by 23
Ferrannini, G., Norhammar, A., Gyberg, V., Mellbin, L., & Rydén, L. (2020) · Diabetes Care · doi:10.2337/dci20-0002 · Cited by 23
Serné, E. H., Roze, S., Buompensiere, M. I., Valentine, W. J., de Portu, S., & de Valk, H. W. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02058-9 · Cited by 24
Trends of Diabetes Epidemic in Korea
Bae, J. C. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0194 · Cited by 23
Adult-onset type 1 diabetes: predictors of major cardiovascular events and mortality
Wei, Y., Andersson, T., Tuomi, T., Nyström, T., & Carlsson, S. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf304 · Cited by 25
The Remnant Lipoprotein Hypothesis of Diabetes-Associated Cardiovascular Disease
Bornfeldt, K. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317163 · Cited by 22
Cardiovascular risk management in people with type 1 diabetes: performance using three guidelines
Varkevisser, R. D. M., Birnie, E., Vollenbrock, C. E., Mul, D., van Dijk, P. R., van der Klauw, M. M., Veeze, H. J., Wolffenbuttel, B. H. R., & Aanstoot, H. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-002765 · Cited by 22
A Review on Diabetes Mellitus its Types, Pathophysiology, Epidermiology and its Global Burden
Patil, S. R., Chavan, A. B., Patel, A., Chavan, P. D., & Bhopale, J. V. (2023) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.2.4.9 · Cited by 25
Tecce, N., Cennamo, G., Rinaldi, M., Costagliola, C., & Colao, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030831 · Cited by 23
Sherr, J. L., Bergford, S., Gal, R. L., Clements, M. A., Patton, S. R., Calhoun, P. M., Beaulieu, L. C., & Riddell, M. C. (2024) · Diabetes Care · doi:10.2337/dc23-2212 · Cited by 22
Karlsson, S. A., Hero, C., Svensson, A., Franzén, S., Miftaraj, M., Guðbjörnsdóttir, S., Eeg‐Olofsson, K., Eliasson, B., & Sundell, K. A. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020309 · Cited by 22
Self-citationWarraich, H. J., & Rana, J. S. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1068-6 · Cited by 23
Nova abordagem para o tratamento da diabetes: da glicemia à doença cardiovascular
Aguíar, C., Duarte, R., & Carvalho, D. M. (2019) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2018.03.013 · Cited by 22
Evaluation of the Finnish Diabetes Risk Score (FINDRISC) for diabetes screening in Kayseri, Turkey
Atayoğlu, A. T., İnanç, N., Başmısırlı, E., & Çapar, A. G. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.01.002 · Cited by 22
Zaccardi, F., Davies, M. J., & Khunti, K. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13929 · Cited by 22
Siasos, G., Skotsimara, G., Oikonomou, E. K., Sagris, Μ., Mystakidi, V. C., Bletsa, E., Stampouloglou, P. K., Theofilis, P., Charalampous, G., & Tousoulis, D. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200417145605 · Cited by 23
Bennet, L., Udumyan, R., Östgren, C. J., Rolandsson, O., Jansson, S. P. O., & Wändell, P. E. (2020) · Diabetologia · doi:10.1007/s00125-020-05279-1 · Cited by 22
Ren, H., Zhao, L., Zou, Y., Wang, Y., Zhang, J., Wu, Y., Zhang, R., Wang, T., Wang, J., Zhu, Y., et al. (2021) · Renal Failure · doi:10.1080/0886022x.2021.1893186 · Cited by 22
Kim, S. J., Kwon, O. D., & Kim, K. S. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01455-3 · Cited by 22
Wargny, M., Croyal, M., Ragot, S., Gand, E., Jacobi, D., Trochu, J.-N., Prieur, X., Le May, C., Goronflot, T., Cariou, B., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01505-9 · Cited by 21
Secreted frizzled-related protein 2 ameliorates diabetic cardiomyopathy by activating mitophagy
Zheng, H., Li, W., Huang, G., Zhu, H., Wen, W., Liu, X., Sun, L., Ma, T., Huang, X., Hu, Y., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166989 · Cited by 21
Cardiovascular disease in type 1 diabetes: a continuing challenge
Orchard, T. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00190-x · Cited by 21
Gouda, P., Zheng, S., Peters, T. M., Fudim, M., Randhawa, V. K., Ezekowitz, J. A., Mavrakanas, T. A., Giannetti, N., Tsoukas, M. A., Lópes, R. D., et al. (2021) · Current Heart Failure Reports · doi:10.1007/s11897-021-00527-w · Cited by 22
Bioactive spermidine nanoparticles for effective cardiovascular recovery and diabetic therapy
Nie, T., Fang, Z., Liu, H., Zhang, X., Fang, Y., Xu, X., Huang, H. W., & Wu, J. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.137353 · Cited by 21
Rydberg, M., Zimmerman, M., Gottsäter, A., Eeg‐Olofsson, K., & Dahlin, L. B. (2022) · Diabetes Care · doi:10.2337/dc22-0829 · Cited by 21
Wang, X., Chen, Y., Huang, Z., Cai, Z., Yu, X., Chen, Z., Li, L., Chen, G., Wu, K., Zheng, H., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1054741 · Cited by 21
Caring for Patients With Diabetes in Stroke Neurology
Kernan, W. N., Forman, R., & Inzucchi, S. E. (2022) · Stroke · doi:10.1161/strokeaha.122.038163 · Cited by 23
Gender gaps in type 1 diabetes care
Bak, J. C. G., Serné, E. H., de Valk, H. W., Valk, N. K., Kramer, M. H. H., Nieuwdorp, M., & Verheugt, C. L. (2023) · Acta Diabetologica · doi:10.1007/s00592-022-02023-6 · Cited by 22
Hu, Y., Yeh, C., Liu, C.-J., Chen, T., Huang, N., & Chou, Y. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003262 · Cited by 22
Chen, P., Wang, B., Zhao, L., Ma, S., Wang, Y., Zhu, Y., Zeng, X., Bai, Z., & Shi, B. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03626-9 · Cited by 21
Lahlou, R. A., Carvalho, F., Pereira, M. J. V. D. C. R., Lopes, J. A., & Silva, L. R. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040454 · Cited by 21
Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
Hinnen, D. A., & Kruger, D. F. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s188705 · Cited by 23
Jermendy, G., Kiss, Z., Rokszin, G., Abonyi‐Tóth, Z., Wittmann, I., & Kempler, P. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107788 · Cited by 22
Carmienke, S., Baumert, J., Gabrys, L., Heise, M., Frese, T., Heidemann, C., & Fink, A. M. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001066 · Cited by 21
Zhou, A., Xiang, Y., Liu, E.-Q., Cai, C., Wu, Y., Yang, L., & Zeng, C. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-01316-z · Cited by 21
Sperlich, S., Beller, J., Epping, J., Safieddine, B., Tetzlaff, J., & Geyer, S. (2020) · Journal of Aging and Health · doi:10.1177/0898264320970324 · Cited by 21
Qiu, Y., Deng, X., Sha, Y., Wu, X., Zhang, P., Chen, K., Zhao, Z., Wei, W., Yang, L., Yuan, G., et al. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s284420 · Cited by 21
Hellgren, M. I., Svensson, A., Franzén, S., Ericsson, Å., Guðbjörnsdóttir, S., Ekström, N., Bertilsson, R., Valentine, W. J., & Malkin, S. J. P. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14376 · Cited by 21
Self-citationCardio- and reno-protective effects of dipeptidyl peptidase III in diabetic mice
Komeno, M., Pang, X., Shimizu, A., Molla, M. R., Yasuda‒Yamahara, M., Kume, S., Rahman, N. I. A., Soh, J. E. C., Nguyen, L. K. C., Amin, M. K. B. A., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100761 · Cited by 21
Macedoni, M., Hovnik, T., Plesnik, E., Kotnik, P., Bratina, N., Battelino, T., & Grošelj, U. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.04.013 · Cited by 22
Metadata
- Authors
- Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S.
- Affiliations
- University of Glasgow (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-04-13
- Volume
- 376
- Issue
- 15
- Pages
- 1407-1418
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2606281213
- Cited by
- 1,389
- References
- 37
- Citations by year
- 2026: 100 · 2025: 144 · 2024: 163 · 2023: 149 · 2022: 184 · 2021: 176 · 2020: 196 · 2019: 140 · 2018: 95 · 2017: 39
- FWCI
- 101.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, type 2 diabetes, cardiovascular disease, mortality, coronary artery disease, cardiovascular hospitalization, Sweden, diabetes registry, standardized incidence rate
- MeSH terms
- Adolescent, Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, Hospitalization, Humans, Male, Middle Aged, Mortality, Registries, Risk Factors, Sweden, Incidence, Proportional Hazards Models, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
